PLx Pharma Winddown Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

PLx Pharma Winddown has a total shareholder equity of $26.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $33.2M and $6.9M respectively.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$25.83m
Eşitlik	US$26.33m
Toplam yükümlülükler	US$6.89m
Toplam varlıklar	US$33.22m

Son finansal sağlık güncellemeleri

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

May 10

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Sep 23

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Jun 15

Recent updates

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

Aug 12

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

May 10

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Nov 03

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Sep 23

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PLXP.Q's short term assets ($30.2M) exceed its short term liabilities ($6.3M).

Uzun Vadeli Yükümlülükler: PLXP.Q's short term assets ($30.2M) exceed its long term liabilities ($582.0K).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PLXP.Q is debt free.

Borcun Azaltılması: PLXP.Q has no debt compared to 5 years ago when its debt to equity ratio was 56.2%.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Insufficient data to determine if PLXP.Q has enough cash runway based on its current free cash flow.

Tahmini Nakit Akışı: Insufficient data to determine if PLXP.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

PLx Pharma Winddown Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

PLx Pharma Winddown Corp. Files Form 15

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Recent updates

PLx Pharma Winddown Corp. Files Form 15

Plx Pharma Winddown Corp. Announces Executive Changes

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022

Consensus forecasts updated

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$16.33

PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

No longer forecast to breakeven

PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

PLx Pharma: First Commercial Launch Makes It Attractive

Consensus forecasts updated

PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month

Consensus revenue estimates fall to US$5.73m

Price target increased to US$21.50

PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August

Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August

Executive Chairman recently bought US$100k worth of stock

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Consensus forecasts updated

Consensus revenue estimates increase to US$6.80m

Earnings beat expectations

Executive Chairman recently bought US$200k worth of stock

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.

Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.

PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 Mg

New 90-day high: US$6.89

New 90-day high: US$6.50

PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration

PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma EPS misses by $0.10

Earnings miss expectations

New 90-day high: US$4.31

PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020

New 90-day high - US$4.18

PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020

PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin